# Study of Liposomal Annamycin in Patients With Refractory or Relapsed Acute Lymphocytic Leukemia

> **NCT00271063** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Callisto Pharmaceuticals** · enrollment: 34 (estimated)

## Conditions studied

- Acute Lymphocytic Leukemia

## Interventions

- **DRUG:** Liposomal Annamycin

## Key facts

- **NCT ID:** NCT00271063
- **Lead sponsor:** Callisto Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2005-10
- **Primary completion:** —
- **Final completion:** 2008-04
- **Target enrollment:** 34 (ESTIMATED)
- **Last updated:** 2007-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00271063

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00271063, "Study of Liposomal Annamycin in Patients With Refractory or Relapsed Acute Lymphocytic Leukemia". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00271063. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*